Mixing, diluting, or repackaging biological products outside the scope of an approved Biologics License Application

This final guidance sets forth FDA’s policy regarding the mixing, diluting, and repackaging

of certain types of biological products that have been licensed under section 351 of the Public Health Service Act (PHS Act) when such activities are not within the scope of the product’s approved biologics license application (BLA) as described in the approved labeling for the product.

See: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM434176.pdf

Posted by Dr. Tim Sandle